Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups, Phase 2a Clinical Trial to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients

NCT06329141 is registered in ClinicalTrials.gov with Glaceum as lead sponsor.

NCT NCT06329141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06329141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups, Phase 2a Clinical Trial to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients
Lead sponsor
Glaceum
Phase
Phase 2
Overall status
Completed
Start date
July 22, 2024
Completion date
January 7, 2026
Enrollment
99 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease